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EDITORIALDecoding Hidden Messages: Can Fecal Host Transcriptomics
Open Pathways to Understanding Environmental Enteropathy?n this issue of Cellular and Molecular Gastroenterology
1Iand Hepatology, Yu et al showed how human RNA
could be isolated from feces and interrogated. They applied
this technology to feces from 259 children in rural Malawi
to show that host messenger RNA (mRNA) transcripts
encoding immune and epithelial cell adhesion proteins
associate with environmental enteric dysfunction (EED),
deﬁned as the percentage of lactulose excretion (%L), as a
measure of barrier dysfunction, growth impairment, or both.
The transcripts identiﬁed include those associated with
broad immunologic responses (T-cell chemokines, immu-
noglobulin Fc fragments, interferon-induced proteins,
neutrophil, and B-cell activators), mediators that dampen
cell responses to growth hormones, and reduced expression
of mucin, epidermal growth factor receptor, and mucous
layer kinase. This ability to noninvasively assess intestinal
mRNA provides an intriguing approach to the difﬁcult
problem of understanding the dynamic interplay occurring
in the relatively inaccessible small-bowel mucosa between
environmental microbes and nutrients and the human host.
Such interactions profoundly affect the delicate absorptive
barrier and inﬂammatory responses of the rapidly renewing
small-bowel mucosa and can determine healthy child
growth and cognitive development. Certainly many will be
concerned that the %L is a controversial and imperfect
assessment of environmental enteric dysfunction, because it
does not include direct assessments of active absorptive
function or local or systemic inﬂammation. Importantly,
however, the investigators analyzed which associations with
%L also were linked to growth impairment over the 3
months after stool collection. These included CLEC7, FCGR2,
FCGR3, IFITM1, IFITM2, LYN, MNDA, and SELL.
This technically impressive achievement was predicated
upon the enrichment of a relatively small pool of eukaryotic-
speciﬁc transcriptomes amid the far greater pool of bacterial
RNA in fecal samples. How then can human fecal tran-
scriptomics enhance our understanding of the etiology and
pathogenesis of EED? First, these ﬁndings reinforce our
conceptual framework that intestinal inﬂammation is
coupled with increased gut permeability. These data also
provide upstream corroboration of protein markers of EED,
such as neopterin (a macrophage or dendritic cell protein
that is produced upon stimulation with interferon-g from
activated T cells) and myeloperoxidase (a marker of
neutrophil activation), which correlate with a-antitrypsin as
a marker of gut permeability in other investigations.2 The
work also shows how one can analyze host pathways to
elucidate mechanisms of health and disease in a manner
that was not previously possible. For example, the in-
vestigators showed decreases in mucin expression andCellular and Molecular Gastroenterology and Hepatology 2016;2:114–1mucous layer kinase transcripts that correlate with in-
creases in immune activation. Perhaps surprisingly, rela-
tively few changes were seen in epithelial cell growth or
restitution pathways, and most of the transcripts associated
with EED were not speciﬁc to the small intestine, where
EED is thought to primarily localize. It is possible that this
reﬂects degradation of mRNA in sloughed epithelial cells,
particularly those from the proximal small intestine that
have had to survive the harsh conditions of the distal small
intestine and colon, and are more subject to degradation or
functional modulations than inﬂammatory cells. Whether
the new technique does bias toward distal small-bowel or
colonic epithelial mRNA will require further study. This may
be facilitated by the development of markers to provide
bowel region speciﬁcity when analyzing fecal samples.
Despite potential technical limitations, the investigators
were able to perform a robust analysis of gene expression.
They then used this to develop a framework for under-
standing the pathogenesis of EED as a condition arising from
decreased mucus production, allowing more intimate asso-
ciation between microbes and the mucosa and promoting
chronic inﬂammation.Whethermucin down-regulation is the
cause (traceable perhaps to variation in mucin-modulating
microbiota such as Akkermansia or pathogens or both,
select nutritional deﬁciencies, or even epigenetic methylation
of CpG islands in speciﬁc regions of MUC2 promoter that
down-regulate MUC2 expression,3–5 or a consequence (sec-
ondary to potential tumor necrosis factor-a–induced inhibi-
tory effects on mucin transcription along with goblet cell
depletion6) of chronic inﬂammation currently is unknown.
Furthermore, whether broad inﬂammatory activation sig-
niﬁes an appropriate attempt to repair a damagedmucosa, as
the investigators suggested, or reﬂects a dysregulated
mucosal response to resident and/or pathogenic microbes as
may occur in conditions of immunocompromise, speciﬁc
nutrient deﬁciency,5 or inﬂammatory bowel diseases, also is
unclear. Future sequential measurements of fecal host tran-
scriptomes layered on other innovative methods such as
multipathogen molecular fecal diagnostics, microbiomics,
and metabonomics (which show perturbed choline and
tryptophan metabolism associated with undernutrition and
metabolic adaptations for catch-up growth)7 should provide a
more complete overview of the global biological system
helping to resolve key questions about EED pathogenesis.
Nevertheless, this work describes an intriguing nonin-
vasive method to interrogate the host responses to micro-
bial and nutritional challenges. In this analysis of young
children in impoverished areas, the data also were used to
develop hypotheses about EED pathogenesis and potential
approaches and biomarkers for assessing innovative15
March 2016 Editorial 115interventions to improve growth and development, not to
mention potential long-term metabolic and cognitive
consequences.
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